Steatohepatitis is an advanced stage of liver disease. While alcohol can be the main cause, it isn't always. Let's look at treatment options and more: ...

Non-alcoholic steatohepatitis often occurs in individuals with metabolic risk factors like obesity, type 2 diabetes, hypothyroidism, deranged lipid profile or raised blood pressure.

North America is anticipated to provide a significant share of non-alcoholic steatohepatitis therapeWilmington, Delaware, United States, July 07, 2023 (GLOBE NEWSWIRE) -- The global non-alcoholic ...

Non-alcoholic steatohepatitis (NASH) is a condition that falls under the umbrella of non-alcoholic fatty liver diseases. About 12 percent of the population in the United States is affected by NASH, ...

Steatohepatitis can arise from alcohol consumption or during the course of certain health conditions, such as hypertension and type 2 diabetes. Treatment for steatohepatitis typically involves ...

The global non-alcoholic steatohepatitis treatment market size was USD 7.70 billion in 2024, estimated at USD 9.85 billion in 2025, and is expected to reach around USD 90.97 billion by 2034 ...

The term ‘non-alcoholic steatohepatitis’ was first proposed by Ludwig et al. 1 in 1980 to denote steatohepatitis in absence of alcohol abuse. Well-established risk factors for non-alcoholic ...

Non-alcoholic steatohepatitis (NASH) is increasing in prevalence, partially because of the pervasiveness of obesity. In this Review, Musso and colleagues discuss potential future approaches to ...